ABCL - AbCellera shares jump after bamlanivimab combo nabs FDA's EUA for COVID-19 treatment

AbCellera (ABCL) shares up nearly 14% premarket after announcing that bamlanivimab, a human antibody discovered by AbCellera and developed with Eli Lilly (LLY), administered with a second Lilly antibody, etesevimab has received Emergency Use Authorization from the FDA for the treatment of mild to moderate COVID-19.The EUA allows the use of the combo in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization.The authorization is based on Phase 3 data from the BLAZE-1 trial. The trial which included more than 1,000 COVID-19 patients, showed that those who received bamlanivimab and etesevimab together had a reduction in hospitalizations of 70% and had no deaths.Lilly plans to manufacture more than 250K doses of the bamlanivimab and etesevimab therapy throughout Q1 2021, and up to a million doses by mid-2021, AbCellera said.Lilly shares were up ~1% premarket.

For further details see:

AbCellera shares jump after bamlanivimab combo nabs FDA's EUA for COVID-19 treatment